Loading...
Back to narrative

NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations

No Surprises Act Risks Will Shrink Margins Yet Foster Adaptation

NUTX logo
NUTX
AnalystLowTarget
Not Invested
Published 05 Sep 2025

Update shared on 12 Dec 2025

Fair value Increased 7.32%
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
485.2%
7D
-7.0%

Narrative Update on Nutex Health

Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate.

What's in the News

  • Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).
  • Nutex Health announced the reopening of Red River ER & Hospital in Sherman, Texas, an 18,500 square foot facility offering 24/7 concierge level emergency care, inpatient suites, and a full service lab with advanced imaging capabilities (company announcement).
  • The company disclosed it will be unable to file its next Form 10 Q with the SEC by the required deadline (SEC filing notice).
  • Nutex Health extended the duration of its share repurchase plan through March 31, 2026 (company announcement).
  • Nutex Health was added to the S&P Global BMI Index, increasing its visibility among institutional investors and index tracking funds (index provider announcement).

Valuation Changes

  • Fair value was raised modestly from $205.00 to $220.00 per share.
  • The discount rate decreased slightly from 7.02 percent to 6.96 percent, supporting a higher valuation.
  • Revenue growth was reduced significantly from 16.97 percent to 3.12 percent, reflecting more conservative top line assumptions.
  • The net profit margin increased sharply from approximately 1.01 percent to 26.94 percent, indicating expectations for substantial margin expansion.
  • The future P/E was lowered materially from 124.0x to 7.43x, implying a less aggressive earnings multiple underlying the valuation.

Have other thoughts on Nutex Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.